Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation

This work is one of our efforts to discover potent anticancer agents. We modified the most promising derivative of our previous work concerned with the development of VEGFR-2 inhibitor candidates. Thirteen new compounds based on benzoxazole moiety were synthesized and evaluated against three human cancer cell lines, namely, breast cancer (MCF-7), colorectal carcinoma (HCT116), and hepatocellular carcinoma (HepG2). The synthesized compounds were also evaluated against VEGFR-2 kinase activity. The biological testing fallouts showed that compound was more potent than standard sorafenib. Such compound showed IC values of 3.43, 2.79, and 2.43 µM against the aforementioned cancer cell lines, respectively, compared to IC values of 4.21, 5.30, and 3.40 µM reported for sorafenib. Compound also was found to exert exceptional VEGFR-2 inhibition activity with an IC value of 0.0554 μM compared to sorafenib (0.0782 μM). In addition, compound revealed excellent cytotoxic effects with IC values of 3.53, 2.94, and 2.76 µM against experienced cell lines, respectively. Furthermore, compounds and were found to inhibit VEGFR-2 kinase activity with IC values of 0.0579 and 0.0741 μM, exceeding that of sorafenib. Compound showed a significant apoptotic effect and arrested the HepG2 cells at the pre-G1 phase. In addition, it exerted a significant inhibition for TNF-α (90.54%) and of IL-6 (92.19%) compared to dexamethasone (93.15%). The molecular docking studies showed that the binding pattern of the new compounds to VEGFR-2 kinase was similar to that of sorafenib.